Biomarin Pharmaceutical Inc (BMRN) Stock Analysis and Metrics

Biomarin Pharmaceutical

NASDAQ: BMRN

$59.33 ▲ +0.47 (+0.79%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap11.41 Bn

P/E42.44

P/S3.52

Div. Yield0.00

Total Debt (Qtr)1.43 Bn

Revenue Growth (1y) (Qtr)2.83

Add ratio to table…

About

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company dedicated to discovering and delivering medicines for patients with genetically defined conditions. Founded in 1997 and headquartered in San Rafael California the company has built a portfolio of eight approved therapies and a deep pipeline of clinical and preclinical candidates that target serious life threatening disorders. Its strategy combines internal research partnerships and acquisitions to bring category defining treatments to market while maintaining a focus on scientific rigor and patient impact.

The company generates revenue primarily from the sale of its approved products which include VOXZOGO for achondroplasia VIMIZIM for mucopolysaccharidosis type IVA NAGLAZYME for mucopolysaccharidosis type VI PALYNZIQ and KUVAN for phenylketonuria ALDURAZYME for mucopolysaccharidosis type I BRINEURA for neuronal ceroid lipofuscinosis type 2 and ROCTAVIAN for severe hemophilia A. In 2025 BioMarin reported total revenues of $3.2 billion driven by strong demand for VOXZOGO which contributed $926.9 million and steady performance across its enzyme therapy franchise. Revenue growth is supported by ongoing commercial expansion of VOXZOGO the integration of recently acquired assets such as BMN 401 from Inozyme and the pending acquisition of Amicus Therapeutics which will add two new enzyme replacement therapies. The company also recorded restructuring charges related to the voluntary withdrawal of ROCTAVIAN from the market in December 2025.

The company operates through the following segments:

• Skeletal Conditions: This segment focuses on the development and commercialization of VOXZOGO a once daily injection that acts as a positive regulator of the fibroblast growth factor receptor 3 signaling pathway to promote endochondral bone growth in achondroplasia and related growth disorders. The segment also includes earlier stage candidates such as BMN 333 a longer acting C‑type natriuretic peptide being studied for achondroplasia and hypochondroplasia and the CANOPY program which evaluates VOXZOGO in hypochondroplasia idiopathic short stature Noonan syndrome Turner syndrome and SHOX deficiency.

• Enzyme Therapies: This segment encompasses the portfolio of enzyme replacement therapies that address lysosomal storage disorders and metabolic conditions. It includes VIMIZIM for MPS IVA NAGLAZYME for MPS VI PALYNZIQ and KUVAN for phenylketonuria ALDURAZYME for MPS I and BRINEURA for CLN2 disease. Manufacturing of ALDURAZYME NAGLAZYME PALYNZIQ and VOXZOGO occurs at the Novato California facility while VIMIZIM and BRINEURA are produced at the Shanbally Cork Ireland site. The segment also manages the PALYNZIQ Risk Evaluation and Mitigation Strategy which requires prescriber and patient training and the availability of auto injectable epinephrine to mitigate anaphylaxis risk.

BioMarin holds a leading position in the rare disease therapeutics market competing with larger biopharmaceutical corporations while leveraging its deep expertise in genetic medicine strong orphan drug exclusivity and a robust pipeline of clinical stage candidates. The company’s intellectual property portfolio includes numerous patents and regulatory exclusivities that provide market protection for its products and create barriers to entry for competitors. Strategic initiatives such as the acquisition of Inozyme and the pending purchase of Amicus are intended to broaden the therapeutic base and strengthen the commercial platform. BioMarin’s ability to integrate internal research with external opportunities supports its goal of delivering first in class or best in class therapies for underserved patient populations.

The company’s products reach patients through a network of specialty pharmacies hospitals government agencies authorized distributors and pharmaceutical wholesalers. Sanofi is the sole customer for ALDURAZYME handling its global distribution marketing and sales. A limited number of customers accounted for approximately 37% of net product revenue in 2025 highlighting concentration in certain channels. BioMarin also relies on third party logistics providers for storage and distribution and collaborates with advertising agencies market research firms and other vendors to support its commercial activities. The commercial organization is structured around the Skeletal Conditions and Enzyme Therapies business units which deploy sales representatives and medical science liaisons to engage physicians in relevant specialties across the United States Europe South America and other international markets.

Investment Thesis

▲ Bull case

BioMarin Pharmaceutical Inc.'s recent Phase 3 CANOPY-HCH-3 trial results for Voxzogo in hypochondroplasia significantly exceed expectations, demonstrating a 2.33 cm/year improvement in annualized growth velocity versus placebo with p<0.0001, alongside statistically significant gains in standing height, height Z-score, and arm span—key functional indicators linked to independence—positioning the drug for potential regulatory approval in Q3 FY26 and sNDA submission to the FDA, with subsequent EMA filings, which could unlock a new patient population of approximately 14,000 globally diagnosed individuals and drive meaningful revenue expansion beyond achondroplasia as early diagnosis efforts have already yielded a 90% increase in identified hypochondroplasia patients and a 70% reduction in average age at diagnosis, creating a robust pipeline of treatment-ready patients ahead of launch. The successful integration of Amicus Therapeutics is already delivering stronger-than-anticipated early performance in 2026, with internal management data showing Galafold and Pombilti+Opfolda revenue for January through April ahead of consensus, supporting the $500 million midpoint guidance contribution for the eight-month post-acquisition period and implying healthy organic year-over-year growth in the high teens to low twenties% range, which, when layered onto BioMarin's existing enzyme therapies portfolio, drives the revised 30% year-over-year enzyme therapies growth guidance and total revenue acceleration to 20% at the midpoint, with over 55% of full-year 2026 revenue expected in the second half due to order timing normalization and two full quarters of Amicus product contribution, setting up a pronounced second-half inflection in both revenue and profitability where two-thirds of non-GAAP diluted EPS is projected to occur in Q3 and Q4. BioMarin Pharmaceutical Inc.'s strategic focus on early diagnosis and treatment initiation, particularly for Voxzogo in infants under two years of age, is gaining traction, with over half of Q1 2026 new patient starts in this cohort and a 10% reduction in average age of treatment initiation, aligning with international consensus guidelines and creating a durable competitive advantage by maximizing long-term therapeutic impact on endochondral bone formation, while the sNDA for full approval of Voxzogo in achondroplasia submitted in April FY26—anticipated for acceptance in Q3—will reinforce the drug's differentiated long-term safety and efficacy profile supported by over 10,000 patient-years of exposure, potentially extending its use lifecycle and strengthening pricing power amid emerging competition.

BioMarin Pharmaceutical Inc.'s recent Phase 3 CANOPY-HCH-3 trial results for Voxzogo in hypochondroplasia significantly exceed expectations, demonstrating a 2.33 cm/year improvement in annualized growth velocity versus placebo with p<0.0001, alongside statistically significant gains in standing height, height Z-score, and arm span—key functional indicators linked to independence—positioning the drug for potential regulatory approval in Q3 FY26 and sNDA submission to the FDA, with subsequent EMA filings, which could unlock a new patient population of approximately 14,000 globally diagnosed individuals and drive meaningful revenue expansion beyond achondroplasia as early diagnosis efforts have already yielded a 90% increase in identified hypochondroplasia patients and a 70% reduction in average age at diagnosis, creating a robust pipeline of treatment-ready patients ahead of launch. The successful integration of Amicus Therapeutics is already delivering stronger-than-anticipated early performance in 2026, with internal management data showing Galafold and Pombilti+Opfolda revenue for January through April ahead of consensus, supporting the $500 million midpoint guidance contribution for the eight-month post-acquisition period and implying healthy organic year-over-year growth in the high teens to low twenties% range, which, when layered onto BioMarin's existing enzyme therapies portfolio, drives the revised 30% year-over-year enzyme therapies growth guidance and total revenue acceleration to 20% at the midpoint, with over 55% of full-year 2026 revenue expected in the second half due to order timing normalization and two full quarters of Amicus product contribution, setting up a pronounced second-half inflection in both revenue and profitability where two-thirds of non-GAAP diluted EPS is projected to occur in Q3 and Q4. BioMarin Pharmaceutical Inc.'s strategic focus on early diagnosis and treatment initiation, particularly for Voxzogo in infants under two years of age, is gaining traction, with over half of Q1 2026 new patient starts in this cohort and a 10% reduction in average age of treatment initiation, aligning with international consensus guidelines and creating a durable competitive advantage by maximizing long-term therapeutic impact on endochondral bone formation, while the sNDA for full approval of Voxzogo in achondroplasia submitted in April FY26—anticipated for acceptance in Q3—will reinforce the drug's differentiated long-term safety and efficacy profile supported by over 10,000 patient-years of exposure, potentially extending its use lifecycle and strengthening pricing power amid emerging competition.

▼ Bear case

BioMarin Pharmaceutical Inc.'s pivotal ENERGY 3 trial for BMN 401 in ENPP1 deficiency delivered a clinically inconclusive outcome, meeting only one of two co-primary endpoints with statistically significant increases in plasma inorganic pyrophosphate but failing to show improvement in the Radiographic Global Impression of Change (RGI-C) score—a critical measure of rickets severity and functional health—along with no positive trends in secondary endpoints including growth Z-score and Rickets Severity Score, raising substantial doubts about the therapy's ability to deliver meaningful clinical benefit despite biochemical success, which analysts interpret as a meaningful clinical failure that materially lowers the probability of near-term commercialization and increases pressure on the company to redirect costly R&D investments toward more promising pipeline assets like BMN 333 or hypochondroplasia expansion, especially given the absence of approved treatments and high infant mortality in this indication. The integration of Amicus Therapeutics introduces near-term financial drag and execution risk, as evidenced by the $31 million first-quarter cost of sales charge from an unsuccessful Naglazyme process qualification campaign that directly impacted GAAP margins and diluted earnings per share by $0.20, with BioMarin acknowledging that pre-close acquisition costs and Amicus-related dilution are weighted toward Q2, suppressing near-term profitability despite expectations of accretion beginning in 2027, while the company's guidance assumes only modest cost synergies in 2026 and relies on uncertain long-term revenue potential projections for Galafold and Pombilti+Opfolda—cited as having roughly $1 billion peak sales potential each in due diligence—without providing concrete near-term commercialization levers beyond diagnosis-driven growth for Galafold and progression-based switching for Pompe, which may prove slower than anticipated in mature markets with entrenched standard-of-care therapies. BioMarin Pharmaceutical Inc.'s reliance on order timing dynamics to explain the disconnect between strong underlying patient demand—such as the 20% year-over-year increase in Voxzogo-treated children—and modest quarterly revenue growth creates vulnerability to macroeconomic and supply chain fluctuations, particularly as the company expects more than 55% of 2026 revenue to be recognized in the second half, making full-year guidance highly sensitive to execution in H2 and exposing investors to potential downside if international order patterns repeat Q4 2025-like stocking effects or if U.S. wholesaler destocking persists, a risk compounded by the ongoing ITC litigation against Ascendis, where an adverse ruling could threaten Voxzogo's U.S. market exclusivity and force costly defensive strategies, including potential federal district court enforcement, despite management's refusal to disclose specific scenarios around appealability or workarounds.

BioMarin Pharmaceutical Inc.'s pivotal ENERGY 3 trial for BMN 401 in ENPP1 deficiency delivered a clinically inconclusive outcome, meeting only one of two co-primary endpoints with statistically significant increases in plasma inorganic pyrophosphate but failing to show improvement in the Radiographic Global Impression of Change (RGI-C) score—a critical measure of rickets severity and functional health—along with no positive trends in secondary endpoints including growth Z-score and Rickets Severity Score, raising substantial doubts about the therapy's ability to deliver meaningful clinical benefit despite biochemical success, which analysts interpret as a meaningful clinical failure that materially lowers the probability of near-term commercialization and increases pressure on the company to redirect costly R&D investments toward more promising pipeline assets like BMN 333 or hypochondroplasia expansion, especially given the absence of approved treatments and high infant mortality in this indication. The integration of Amicus Therapeutics introduces near-term financial drag and execution risk, as evidenced by the $31 million first-quarter cost of sales charge from an unsuccessful Naglazyme process qualification campaign that directly impacted GAAP margins and diluted earnings per share by $0.20, with BioMarin acknowledging that pre-close acquisition costs and Amicus-related dilution are weighted toward Q2, suppressing near-term profitability despite expectations of accretion beginning in 2027, while the company's guidance assumes only modest cost synergies in 2026 and relies on uncertain long-term revenue potential projections for Galafold and Pombilti+Opfolda—cited as having roughly $1 billion peak sales potential each in due diligence—without providing concrete near-term commercialization levers beyond diagnosis-driven growth for Galafold and progression-based switching for Pompe, which may prove slower than anticipated in mature markets with entrenched standard-of-care therapies. BioMarin Pharmaceutical Inc.'s reliance on order timing dynamics to explain the disconnect between strong underlying patient demand—such as the 20% year-over-year increase in Voxzogo-treated children—and modest quarterly revenue growth creates vulnerability to macroeconomic and supply chain fluctuations, particularly as the company expects more than 55% of 2026 revenue to be recognized in the second half, making full-year guidance highly sensitive to execution in H2 and exposing investors to potential downside if international order patterns repeat Q4 2025-like stocking effects or if U.S. wholesaler destocking persists, a risk compounded by the ongoing ITC litigation against Ascendis, where an adverse ruling could threaten Voxzogo's U.S. market exclusivity and force costly defensive strategies, including potential federal district court enforcement, despite management's refusal to disclose specific scenarios around appealability or workarounds.

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Contract with Customer, Sales Channel Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password